

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 4, 2009.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

STATEMENT OF SUBSTANCE OF INTERVIEW
Examining Group 1617
Patent Application
Docket No. MET.037CXT
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Yong Soo Chong
Art Unit : 1617
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
Serial No. : 09/900,364
Filed : July 5, 2001
Confirm. No. : 7049
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes

MS ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. §1.133

The applicants wish to thank Examiner Chong for the courtesy of the telephonic examiner interview conducted on February 17, 2009 with the undersigned. The remarks set forth in the Interview Summary Form that accompanied the Notice of Allowability dated February 27, 2009 are consistent with the substance of that interview and are believed to address the outstanding issues as discussed during the interview. Permission was granted by the undersigned during the interview to cancel claims 147-179 in order to remove method claims from examination.

Respectfully submitted,

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950

FCE/jnw